JP2019534893A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534893A5
JP2019534893A5 JP2019533297A JP2019533297A JP2019534893A5 JP 2019534893 A5 JP2019534893 A5 JP 2019534893A5 JP 2019533297 A JP2019533297 A JP 2019533297A JP 2019533297 A JP2019533297 A JP 2019533297A JP 2019534893 A5 JP2019534893 A5 JP 2019534893A5
Authority
JP
Japan
Prior art keywords
compound according
ipr
optionally substituted
cancer
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534893A (ja
JP7100639B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/050106 external-priority patent/WO2018048806A1/en
Publication of JP2019534893A publication Critical patent/JP2019534893A/ja
Publication of JP2019534893A5 publication Critical patent/JP2019534893A5/ja
Application granted granted Critical
Publication of JP7100639B2 publication Critical patent/JP7100639B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533297A 2016-09-06 2017-09-05 Cxcr4アンタゴニストおよび使用方法 Expired - Fee Related JP7100639B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662384132P 2016-09-06 2016-09-06
US62/384,132 2016-09-06
US201762505064P 2017-05-11 2017-05-11
US62/505,064 2017-05-11
PCT/US2017/050106 WO2018048806A1 (en) 2016-09-06 2017-09-05 Cxcr4 antagonists and methods of use

Publications (3)

Publication Number Publication Date
JP2019534893A JP2019534893A (ja) 2019-12-05
JP2019534893A5 true JP2019534893A5 (https=) 2020-08-20
JP7100639B2 JP7100639B2 (ja) 2022-07-13

Family

ID=61281979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533297A Expired - Fee Related JP7100639B2 (ja) 2016-09-06 2017-09-05 Cxcr4アンタゴニストおよび使用方法

Country Status (6)

Country Link
US (2) US10351601B2 (https=)
EP (1) EP3509612A4 (https=)
JP (1) JP7100639B2 (https=)
CN (1) CN109922818B (https=)
CA (1) CA3032885C (https=)
WO (1) WO2018048806A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639379B2 (en) * 2017-09-05 2020-05-05 Mainline Biosciences Llc High affinity CXCR4 selective binding conjugate and method for using the same
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
CN115003684A (zh) * 2020-01-26 2022-09-02 主线生物科学有限公司 同位素标记的选择性cxcr4结合肽偶联物及其制备和使用方法
CN118852348A (zh) * 2022-02-11 2024-10-29 C-比奥麦克斯有限公司 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途
GB2628421A (en) * 2023-03-24 2024-09-25 Syntherix Ltd Peptides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60103052T2 (de) * 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
EP1582207A4 (en) * 2002-12-26 2008-03-05 Ajinomoto Kk HEMMER FOR OUTBREAKING AND PROGREDIENCE OF LIVER CANCER
CA2569807A1 (en) * 2004-06-18 2005-12-29 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of hiv infections
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
CL2008001467A1 (es) * 2007-05-30 2008-12-05 Lilly Co Eli Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
JP6294227B2 (ja) * 2011-10-07 2018-03-14 ポリフォー・アクチェンゲゼルシャフトPolyphor Ag Fpr1の阻害剤としてのテンプレート固定ペプチド模倣薬
CN102626522B (zh) 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
JP6047231B2 (ja) 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトPolyphor Ag β−ヘアピンペプチド模倣薬
US9790286B2 (en) * 2013-01-02 2017-10-17 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis

Similar Documents

Publication Publication Date Title
JP2019534893A5 (https=)
JP6966678B2 (ja) Nk細胞におけるサイトカイン誘導性sh2タンパク質の阻害
JP7307744B2 (ja) がん治療のための1-(ピペリジノカルボニルメチル)-2-オキソピペラジン誘導体
JP7013369B2 (ja) Ezh2阻害剤により卵巣の悪性ラブドイド腫瘍(mrto)/高カルシウム血症型の卵巣の小細胞癌(sccoht)を処置するための方法
EP2958571B1 (en) Dna hypomethylating agents for cancer therapy
JP2016505586A5 (https=)
JP2019503167A5 (https=)
JP2019527728A5 (https=)
JP2018532690A5 (https=)
JP2013518107A5 (https=)
JP2013544846A5 (https=)
JP2017525730A5 (https=)
JP2017509586A5 (https=)
JP2004534850A5 (https=)
JP2012525393A5 (https=)
JP2020532496A5 (https=)
WO2011148083A4 (fr) Peptide en tant que médicament, en particulier pour le traitement du cancer
JP2020097577A5 (https=)
JP2009511508A5 (https=)
JP2019519512A5 (https=)
JP2015520770A5 (https=)
CN108697729A (zh) 新型GLUT抑制剂rapaglutin及其用途
JP2022174752A (ja) Crebbp関連癌の治療法
JP2016531885A5 (https=)
JP2011518168A5 (https=)